MAY 18, 2023 | 1-7:30PM ET
MassBio Hub | 700 Technology Square 5th floor
MPM, BioImpact Capital Sponsored Reception
MAY 18, 2023 | 1-7:30PM ET
MassBio Hub | 700 Technology Square 5th floor
MPM, BioImpact Capital Sponsored Reception
For the 2023 theme we will discuss and debate factors contributing to the limited translation we've observed in the oncology clinical pipeline. We will dissect the theme across three major areas:
The summit is off the record and aims to facilitate a broad discussion on what is required to improve the translation of the future oncology pipeline.
Glenn Dranoff
Global Head of Immuno-Oncology,
Novartis Institutes for Biomedical Research (NIBR)
Uciane Scarlett
Principal, MPM Capital
Luke Timmerman
Founder & Editor, Timmerman Report
Dennis Chang
Managing Director, Clarion
Prashant Girinath
Partner, Greenberg Traurig
Jeffrey Bockman
EVP, Head of Oncology, Lumanity
1:00 p.m. | Registration
1:30 p.m. | Welcome Remarks
1:40 p.m. | Research fire-side chat: Recent breakthroughs in preclinical & clinical translation
2:20 p.m. | Innovation Bridge presentation: Title TBD
2:50 p.m. | Innovation debate-style panel: Where is the problem – Implementation vs. Innovation?
3:50 p.m. | People round table: Skills required to enable better translation from bench to clinic
4:50 p.m. | Closing Remarks
5:00 – 7:30 p.m. | MPM, BioImpact Capital hosted Reception
Summit: MassBio Hub | 700 Technology Square 5th floor, Cambridge, MA 02139
Reception: MassBio Hub | 700 Technology Square 4th floor, Cambridge, MA 02139
5th Annual Emerging Frontiers in Oncology
Copyright © 2023 Emerging Frontiers in Oncology - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.